Literature DB >> 8537052

Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy.

J Kjeldsen1, O B Schaffalitzky de Muckadell, P Junker.   

Abstract

Crohn's disease is characterised by gradual development of intestinal fibrotic lesions containing large amounts of collagen type I, III, and V. Measurement of circulating connective tissue metabolites has emerged as a useful tool for assessment of fibroproliferative activity in various diseases. Serum concentrations of procollagen peptides, N-terminal propeptide of type III procollagen (PII-INP), and C-terminal propeptide of type I procollagen (PICP), reflect the synthesis rate of the parent collagens, while the C-terminal telopeptide of type I collagen (ICTP) reflects its degradation. S-PIIINP, S-PICP, and S-ICTP were measured by radioimmunoassays in 29 patients with active Crohn's disease. S-ICTP was significantly increased, median 6.2 micrograms/l (95% CI 5.2 to 8.7 micrograms/l) versus controls 2.6 micrograms/l (2.5 to 2.7 micrograms/l) (p < 0.0001), S-PICP reduced, 100 micrograms/l (80 to 110 micrograms/l) versus 132 micrograms/l (124 to 141 micrograms/l) (p = 0.001), and S-PIIINP did not differ from controls. Patients with sustained clinical remission during prednisolone therapy exhibited an increase in S-PICP (p = 0.0052). S-PIIINP changed significantly (p = 0.0002), however, exhibiting a biphasic pattern. S-ICTP decreased (p = 0.015) in treatment responders but remained above the upper normal limit even when clinical remission had been achieved. Non-responders showed no significant changes in any of the marker molecules of collagen synthesis or degradation. Correlations were found between S-PIIINP and S-PICP (p < 0.005) and S-ICTP (p < 0.02), and between S-ICTP and S-orosomucoid (p < 0.005) and S-C reactive protein (p < 0.02). By contrast, there was no relation between the connective tissue metabolites and Harvey Bradshaw Index. These data provide evidence that collagen I degradation is increased not only in active Crohn's disease, but also in patients entering clinical remission. The concurrent normal/low-normal values of markers of collagen formation may reflect a changed local or systemic elimination of the propeptides.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8537052      PMCID: PMC1382943          DOI: 10.1136/gut.37.6.805

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  36 in total

1.  Cellular localization of procollagen gene transcripts in inflammatory bowel diseases.

Authors:  H Matthes; H Herbst; D Schuppan; A Stallmach; S Milani; H Stein; E O Riecken
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682

2.  Increased serum concentrations of type I procollagen C-terminal propeptide and osteocalcin during a short course of calcitriol administration to adult male volunteers.

Authors:  J Gram; J Bollerslev; H K Nielsen; P Junker
Journal:  Acta Endocrinol (Copenh)       Date:  1991-12

3.  Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease.

Authors:  A Stallmach; D Schuppan; H H Riese; H Matthes; E O Riecken
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

4.  Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation.

Authors:  J Risteli; I Elomaa; S Niemi; A Novamo; L Risteli
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

5.  Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells.

Authors:  B Smedsrød; J Melkko; L Risteli; J Risteli
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

6.  External thoracic duct-venous shunt in conscious pigs for long term studies of connective tissue metabolites in lymph.

Authors:  L T Jensen; H P Olesen; J Risteli; I Lorenzen
Journal:  Lab Anim Sci       Date:  1990-11

7.  Serum markers of collagen synthesis and degradation in skin diseases. Altered levels in diseases with systemic manifestation and during systemic glucocorticoid treatment.

Authors:  P Autio; J Risteli; U Kiistala; L Risteli; J Karvonen; A Oikarinen
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

8.  Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry.

Authors:  E F Eriksen; P Charles; F Melsen; L Mosekilde; L Risteli; J Risteli
Journal:  J Bone Miner Res       Date:  1993-02       Impact factor: 6.741

9.  Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen.

Authors:  A Oikarinen; P Autio; J Vuori; K Väänänen; L Risteli; U Kiistala; J Risteli
Journal:  Br J Dermatol       Date:  1992-02       Impact factor: 9.302

10.  Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma.

Authors:  I Elomaa; P Virkkunen; L Risteli; J Risteli
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

View more
  16 in total

1.  Basement membrane components.

Authors:  A C Y Li; R P H Thompson
Journal:  J Clin Pathol       Date:  2003-12       Impact factor: 3.411

Review 2.  Assessment of stricturing Crohn's disease: Current clinical practice and future avenues.

Authors:  Dominik Bettenworth; Tobias M Nowacki; Friederike Cordes; Boris Buerke; Frank Lenze
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

3.  Effects of surgery on peripheral N-terminal propeptide of type III procollagen in patients with Crohn's disease.

Authors:  Matilde De Simone; Michele M Ciulla; Ugo Cioffi; Luca Poggi; Barbara Oreggia; Roberta Paliotti; Fiorenzo Botti; Alberto Carrara; Fiorenza Agosti; Alessandro Sartorio; Ettore Contessini-Avesani
Journal:  J Gastrointest Surg       Date:  2007-08-09       Impact factor: 3.452

4.  Association Between Plasma Level of Collagen Type III Alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn's Disease.

Authors:  Cortney R Ballengee; Ryan W Stidham; Chunyan Liu; Mi-Ok Kim; Jarod Prince; Kajari Mondal; Robert Baldassano; Marla Dubinsky; James Markowitz; Neal Leleiko; Jeffrey Hyams; Lee Denson; Subra Kugathasan
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-10       Impact factor: 11.382

Review 5.  Biomarkers of intestinal fibrosis - one step towards clinical trials for stricturing inflammatory bowel disease.

Authors:  Paolo Giuffrida; Massimo Pinzani; Gino R Corazza; Antonio Di Sabatino
Journal:  United European Gastroenterol J       Date:  2016-03-21       Impact factor: 4.623

6.  Extracellular Matrix Fragments of the Basement Membrane and the Interstitial Matrix Are Serological Markers of Intestinal Tissue Remodeling and Disease Activity in Dextran Sulfate Sodium Colitis.

Authors:  Majken Lindholm; Tina Manon-Jensen; Gunvor Iben Madsen; Aleksander Krag; Morten Asser Karsdal; Jens Kjeldsen; Joachim Høg Mortensen
Journal:  Dig Dis Sci       Date:  2019-05-24       Impact factor: 3.199

Review 7.  Collagen in colon disease.

Authors:  Michael Stumpf; Carsten Johannes Krones; Uwe Klinge; Rafael Rosch; Karsten Junge; Volker Schumpelick
Journal:  Hernia       Date:  2006-12       Impact factor: 4.739

8.  Serum laminin and collagen IV in inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; P Dimoulios; E Vardas; M Roussomoustakaki; A N Maniatis; E A Kouroumalis
Journal:  J Clin Pathol       Date:  2003-11       Impact factor: 3.411

9.  Elevated serum values of procollagen III peptide (PIIIP) in patients with ulcerative colitis who will develop pseudopolyps.

Authors:  Zarko Babic; Vjekoslav Jagić; Zvonko Petrović; Ante Bilić; Kapetanović Dinko; Goranka Kubat; Rosana Troskot; Mira Vukelić
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

10.  Endotrophin and C6Ma3, serological biomarkers of type VI collagen remodelling, reflect endoscopic and clinical disease activity in IBD.

Authors:  Majken Lindholm; Line E Godskesen; Tina Manon-Jensen; Jens Kjeldsen; Aleksander Krag; Morten A Karsdal; Joachim H Mortensen
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.